Moreover, the novelty of this study is highlighted by two key advancements within the LAC12aGE platform: (i) a simpler and technologically easier approach to implement by preserving an unmodified spacer region, enabling seamless adaptation to various targets without requiring additional optimization; (ii) the first demonstration of in vivo HGF gene knockout and the subsequent apoptosis in cancer cells for tumor therapy. The gene discussed is HGF; the disease is neoplasm.